Now Approved

New Oral Therapeutic


Advancing new hope for
people with kidney disease


Making a difference by
challenging the status quo


We are better together

A trusted leader in the renal community delivering unique products to people with kidney disease.

We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.

VAFSEO® (vadadustat) is approved for use in 34 countries and is now approved by the U.S. Food & Drug Administration.

Be part of a passionate team working to protect the kidneys and to innovate for better lives

Nearly 37 million Americans

are currently affected by chronic kidney disease.

Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible.

Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Available at: Accessed: September 3, 2019.


For the latest news from Akebia, visit our Investors page.

BC-0014   (v6.0)   03/24

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us